Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab.

IF 1 Q4 ONCOLOGY Melanoma Management Pub Date : 2020-02-12 DOI:10.2217/mmt-2019-0020

Quaovi H Sodji, Paulina M Gutkin, Susan M Swetter, Sunil A Reddy, Susan M Hiniker, Susan J Knox

引用次数: 0

Abstract

Aim: We previously reported a prospective trial evaluating the safety and efficacy of combining ipilimumab and radiation therapy in patients with metastatic melanoma. Herein, we provide a long-term update on patients with complete response (CR) or partial response (PR).

Patients & methods: We continued to follow these patients with serial imaging including computed tomography, PET or MRI.

Results: Two of the three patients with CR are still alive and without evidence of melanoma but with chronic treatment-induced hypophysitis. The third patient died of hepatocellular carcinoma, but with no evidence of melanoma. Among the three patients with PR, two achieved CR after pembrolizumab monotherapy.

Conclusion: This long-term follow up reveals the striking durability of the CRs, which appears to correlate with a grade 2-3 hypophysitis.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

转移性黑色素瘤患者接受放疗和伊匹单抗联合治疗后反应的持久性。

目的：我们曾报道过一项前瞻性试验，对转移性黑色素瘤患者联合使用伊匹单抗和放疗的安全性和有效性进行了评估。在此，我们提供了完全应答（CR）或部分应答（PR）患者的长期最新情况：我们继续对这些患者进行连续成像随访，包括计算机断层扫描、正电子发射计算机断层扫描或核磁共振成像：结果：三位 CR 患者中有两位仍然存活，没有黑色素瘤的迹象，但患有慢性治疗诱发的肾上腺皮质功能减退症。第三名患者死于肝细胞癌，但没有黑色素瘤的证据。在三位PR患者中，有两位在接受pembrolizumab单药治疗后达到了CR：结论：长期随访显示，CR具有显著的持久性，这似乎与2-3级肾上腺皮质功能减退相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.